Financial News

Financial Report: Regeneron

Global Eylea sales increased 13% to $1.7 billion in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron 2Q Revenues: $1.6 billion (+9%) 2Q Earnings: $551 million (+42%) YTD Revenues: $3.1 billion (+12%) YTD Earnings: $1.0 billion (+62%) Comments: U.S. sales of EYLEA (aflibercept) Injection were up 8% to $992 million in the quarter and global sales increased 13% to $1.7 billion. The company recently submitted a supplemental Biologics License Application (sBLA) for EYLEA for the treatment of diabetic retinopathy and submitted an sBLA for EYLEA in a pre-filled syringe. Bayer records ne...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters